Introduction
Stopping a GLP-1 medicine often leads to weight regain, on average, in withdrawal studies. In the STEP 1 extension, participants regained about two-thirds of their prior semaglutide-associated weight loss during the following year.
In SURMOUNT-4, people switched from tirzepatide to placebo regained 14.0% from randomization through week 88, while continued treatment produced a further 5.5% average loss.
What semaglutide withdrawal data show
The STEP 1 extension followed a subset after weekly semaglutide 2.4 mg and the lifestyle intervention ended. Average body weight rose by 11.6 percentage points over the following year, described by the authors as about two-thirds of the prior loss. Several cardiometabolic improvements moved toward baseline during follow-up.
Current telehealth prices and providers
These rows come from Telehealth Ledger's canonical catalog. A low headline price only ranks when medication is included and the continuing or prepaid basis is comparable.
Pallas Health
Wegovy · Brand-name injection · medication included
Price source · checked 22 August 2026GobyMeds
Wegovy® · Weekly injection · medication included
Price source · checked 2 September 2026Sprout Health
Wegovy® · Weekly injection · medication included
Price source · checked 2 August 2026Pallas Health
Zepbound · Brand-name injection · medication included
Price source · checked 22 August 2026GobyMeds
Zepbound® · Weekly injection · medication included
Price source · checked 2 September 2026Sprout Health
Zepbound® · Weekly injection · medication included
Price source · checked 2 August 2026- Hone Health: Estimated from $349/mo plus membershipMedication or membership billed separately
Gala Health
Ozempic® · Weekly injection · medication included
Price source · checked 2 August 2026Pallas Health
Ozempic · Brand-name injection · medication included
Price source · checked 22 August 2026Pallas Health
Mounjaro · Brand-name injection · medication included
Price source · checked 22 August 2026Eligibility, prescribed quantity, state availability, pharmacy fulfillment, shipping, supplies, and follow-up can change the final cost. Unknown fields remain unknown.
What tirzepatide maintenance data show
SURMOUNT-4 included a 36-week tirzepatide lead-in, then randomized participants to continue tirzepatide or switch to placebo. From randomization to week 88, the continued-treatment group had a further 5.5% average weight reduction, while the placebo-switch group had 14.0% average regain.
| Decision point | What the cited evidence can answer |
|---|---|
| Exact product | Confirm the approved indication, route, and formulation |
| Outcome evidence | Keep direct trials separate from indirect study comparisons |
| Practical fit | Review safety history, other medicines, follow-up, and access |
How to plan a treatment change
A treatment change is a good time to review the reason for stopping, diabetes medicines, symptom history, nutrition and activity support, access, and future goals. People using insulin or a sulfonylurea need a coordinated diabetes plan before a GLP-1 medicine changes because the rest of the regimen may need reassessment.
Plan the transition
A clinician can review why treatment is changing, glucose goals, other medicines, prior symptoms, nutrition and activity support, access, and preference.
Diabetes adds medication questions
People using insulin or a secretagogue need a coordinated plan before a GLP-1 change.
Avoid abrupt self-switching
A price change, supply concern, or social-media suggestion does not replace a product-specific clinical review.
What the cited sources establish
The withdrawal evidence is study-specific. The STEP 1 extension followed a semaglutide subgroup after treatment and lifestyle intervention stopped, while SURMOUNT-4 randomized participants after a tirzepatide lead-in to continue treatment or switch to placebo. Both studies inform maintenance conversations, but neither provides a personal stopping timetable.
The two withdrawal studies differ in design, which matters when reading their numbers. STEP 1 extension participants stopped both semaglutide and the trial lifestyle intervention, while SURMOUNT-4 participants first completed a tirzepatide lead-in before randomization. The shared practical point is that maintenance deserves planning before an interruption happens, especially when diabetes care, adverse effects, cost, or a pregnancy plan is driving the change.
Before a planned interruption, the care team can decide what outcome will be watched next. For some people that will include body weight and appetite; for people with diabetes it can also include glucose management and the rest of the diabetes regimen. A record of prior adverse effects and the reason for the change helps distinguish a short access disruption from a broader change in treatment strategy. The withdrawal trials support preparing for that transition instead of treating it as an afterthought.
Questions that change the next review
A stopping discussion should identify why the change is being considered and what else must change with it. Diabetes medicines, symptom history, nutrition support, access, pregnancy plans, and the possibility of future treatment alternatives all belong in the handoff plan. The relevant clinician can also explain which outcomes to follow after a transition.
The transition plan can name the clinician responsible for diabetes medicines, the follow-up timing, and the symptoms or outcomes that warrant earlier contact. That turns trial withdrawal findings into a usable care conversation.
Product details that still need verification
Regain averages do not prove that one person will regain at the same rate or that continuing treatment is always the right choice. This article does not supply a taper, restart schedule, or substitute regimen. A supply or price disruption still requires product-specific clinical review before a medication change.
Withdrawal evidence is an average, not an individual's exact outcome. Stopping is not a personal failure. Diabetes medicines need review before a GLP-1 change. Do not restart, taper, or switch from a generic schedule. Semaglutide and tirzepatide withdrawal studies found substantial average regain after treatment stopped, while continued treatment better maintained loss in the studied groups. The personal plan should be clinician-led. The next step is a clinician-led review of the exact product and your situation.
Use the current product label and prompt clinical care for urgent symptoms or medication changes.
Common questions
- What does the evidence show about What Happens When You Stop a GLP-1? What Withdrawal Trials Show About Weight Regain?
- Semaglutide and tirzepatide withdrawal studies found substantial average regain after treatment stopped, while continued treatment better maintained loss in the studied groups. The personal plan should be clinician-led.
- Can I use this as dosing or switching advice?
- No. This page excludes personalized dosing, conversions, and self-directed treatment changes.
- What should I check before acting?
- Check the current product label, the exact formulation, and the plan with the prescribing clinician.
- Why are labels named so often?
- Products can share an ingredient while having different approved uses, formulations, warnings, and evidence.
Use evidence to improve the next clinical conversation
Semaglutide and tirzepatide withdrawal studies found substantial average regain after treatment stopped, while continued treatment better maintained loss in the studied groups. The personal plan should be clinician-led. The next step is a clinician-led review of the exact product and your situation.
Sources
- Clinical study recordPubMed · Accessed 28 August 2026
Primary evidence supporting what happens when you stop GLP-1.
- Clinical study recordPubMed · Accessed 28 August 2026
Primary evidence supporting what happens when you stop GLP-1.
- Clinical guidelineAmerican Diabetes Association · Accessed 28 August 2026
Primary evidence supporting what happens when you stop GLP-1.
- Clinical guidelineAmerican Diabetes Association · Accessed 28 August 2026
Primary evidence supporting what happens when you stop GLP-1.
- FDA primary materialFDA · Accessed 28 August 2026
Primary evidence supporting what happens when you stop GLP-1.
Refresh triggers
- A new FDA label or Medication Guide
- A new major clinical-trial publication
- An ADA or AGA guideline update
- A material change to the verified provider registry